Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide versus insulin glargine, both with lispro, in type 2 diabetes
2010-019223-55Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline at Week 26. Started May 2010; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019223-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019223-55.